دورية أكاديمية
أعرض في EDS

Antibody reactions of horses against various domains of the EHV-1 receptor-binding protein gD1.

التفاصيل البيبلوغرافية
العنوان: Antibody reactions of horses against various domains of the EHV-1 receptor-binding protein gD1.
المؤلفون: Schramm A; Institute of Virology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland., Ackermann M; Institute of Virology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland., Eichwald C; Institute of Virology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland., Aguilar C; Institute of Virology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland., Fraefel C; Institute of Virology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland., Lechmann J; Institute of Virology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
المصدر: PloS one [PLoS One] 2024 Jul 12; Vol. 19 (7), pp. e0301987. Date of Electronic Publication: 2024 Jul 12 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Herpesvirus 1, Equid*/immunology , Antibodies, Viral*/immunology , Antibodies, Viral*/blood , Viral Envelope Proteins*/immunology , Horse Diseases*/virology , Horse Diseases*/immunology , Horse Diseases*/prevention & control, Animals ; Horses/immunology ; Herpesvirus 4, Equid/immunology ; Herpesviridae Infections/veterinary ; Herpesviridae Infections/immunology ; Herpesviridae Infections/virology ; Cross Reactions/immunology ; Enzyme-Linked Immunosorbent Assay ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/blood ; Protein Domains/immunology
مستخلص: Equid alphaherpesviruses 1 (EHV-1) and 4 (EHV-4) are closely related and both endemic in horses worldwide. Both viruses replicate in the upper respiratory tract, but EHV-1 may additionally lead to abortion and equine herpesvirus myeloencephalopathy (EHM). We focused on antibody responses in horses against the receptor-binding glycoprotein D of EHV-1 (gD1), which shares a 77% amino acid identity with its counterpart in EHV-4 (gD4). Both antigens give rise to cross-reacting antibodies, including neutralizing antibodies. However, immunity against EHV-4 is not considered protective against EHM. While a diagnostic ELISA to discriminate between EHV-1 and EHV-4 infections is available based on type-specific fragments of glycoprotein G (gG1 and gG4, respectively), the type-specific antibody reaction against gD1 has not yet been sufficiently addressed. Starting from the N-terminus of gD1, we developed luciferase immunoprecipitation system (LIPS) assays, using gD1-fragments of increasing size as antigens, i.e. gD1_83 (comprising the first 83 amino acids), gD1_160, gD1_180, and gD1_402 (the full-length molecule). These assays were then used to analyse panels of horse sera from Switzerland (n = 60) and Iceland (n = 50), the latter of which is considered EHV-1 free. We detected only one true negative horse serum from Iceland, whereas all other sera in both panels were seropositive for both gG4 (ELISA) and gD1 (LIPS against gD1_402). In contrast, seropositivity against gG1 was rather rare (35% Swiss sera; 14% Icelandic sera). Therefore, a high percentage of antibodies against gD1 could be attributed to cross-reaction and due to EHV-4 infections. In contrast, the gD1_83 fragment was able to identify sera with type-specific antibodies against gD1. Interestingly, those sera stemmed almost exclusively from vaccinated horses. Although it is uncertain that the N-terminal epitopes of gD1 addressed in this communication are linked to better protection, we suggest that in future vaccine developments, type-common antigens should be avoided, while a broad range of type-specific antigens should be favored.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Schramm et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Res Vet Sci. 1990 Mar;48(2):235-9. (PMID: 2159176)
J Virol. 2022 Sep 14;96(17):e0107422. (PMID: 35938869)
Res Vet Sci. 2008 Dec;85(3):605-11. (PMID: 18336849)
Vet J. 2009 Jun;180(3):279-89. (PMID: 18805030)
Vet Immunol Immunopathol. 2006 May 15;111(1-2):15-30. (PMID: 16476492)
Equine Vet J. 1992 Jul;24(4):256-9. (PMID: 1323457)
Vaccine. 2015 Oct 13;33(42):5588-5597. (PMID: 26384446)
J Virol. 1993 Oct;67(10):6332-8. (PMID: 7690425)
J Equine Vet Sci. 2020 Apr;87:102923. (PMID: 32172913)
Vet J. 2005 Jul;170(1):14-23. (PMID: 15993786)
Animals (Basel). 2021 Sep 29;11(10):. (PMID: 34679874)
Protein Sci. 2023 Nov;32(11):e4792. (PMID: 37774136)
J Gen Virol. 2017 Jun;98(6):1439-1454. (PMID: 28631601)
Nat Methods. 2022 Jun;19(6):679-682. (PMID: 35637307)
Transl Res. 2015 Feb;165(2):325-35. (PMID: 25241936)
Arch Virol. 1995;140(2):245-58. (PMID: 7710353)
J Gen Virol. 2021 Oct;102(10):. (PMID: 34704922)
BMC Biotechnol. 2005 Aug 18;5:22. (PMID: 16109166)
Vet Microbiol. 2013 Nov 29;167(1-2):123-34. (PMID: 23890672)
J Virol. 2012 Feb;86(4):2031-44. (PMID: 22171258)
J Autoimmun. 2017 Sep;83:12-21. (PMID: 28479213)
Vet Clin North Am Equine Pract. 1997 Apr;13(1):53-72. (PMID: 9106343)
Nature. 2021 Aug;596(7873):583-589. (PMID: 34265844)
J Gen Virol. 1996 Jan;77 ( Pt 1):75-82. (PMID: 8558130)
Res Vet Sci. 2009 Apr;86(2):339-44. (PMID: 18649902)
Vet Microbiol. 1999 Aug 16;68(1-2):15-25. (PMID: 10501158)
Vet Microbiol. 2010 Jun 16;143(1):21-8. (PMID: 20202764)
Equine Vet J. 2023 May;55(3):389-404. (PMID: 35946376)
Res Vet Sci. 2013 Feb;94(1):170-7. (PMID: 22862856)
BMC Biotechnol. 2018 Nov 16;18(1):73. (PMID: 30445953)
J Vet Intern Med. 2009 May-Jun;23(3):450-61. (PMID: 19645832)
J Gen Virol. 1998 May;79 ( Pt 5):1197-203. (PMID: 9603335)
Arch Virol. 2021 Feb;166(2):571-579. (PMID: 33410993)
J Virol. 2006 Apr;80(8):4047-60. (PMID: 16571821)
Vet Microbiol. 2015 Apr 17;176(3-4):219-28. (PMID: 25666453)
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Viral Envelope Proteins)
0 (glycoprotein D, Equid herpesvirus 1)
0 (Antibodies, Neutralizing)
تواريخ الأحداث: Date Created: 20240712 Date Completed: 20240712 Latest Revision: 20240714
رمز التحديث: 20240714
مُعرف محوري في PubMed: PMC11244823
DOI: 10.1371/journal.pone.0301987
PMID: 38995916
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0301987